{"id":49477,"date":"2022-10-11T13:02:00","date_gmt":"2022-10-11T11:02:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/"},"modified":"2022-10-11T13:02:00","modified_gmt":"2022-10-11T11:02:00","slug":"metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/","title":{"rendered":"Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies"},"content":{"rendered":"
\n

\n\u2022 State-of-the-art GMP facility will support advancement of Metagenomi\u2019s lead pipeline programs and existing partnerships<\/i>\n<\/p>\n

\n\u2022 New facility at Metagenomi\u2019s Emeryville, CA headquarters delivers on strategic growth plans following successful Series B financing earlier this year<\/i>\n<\/p>\n

EMERYVILLE, Calif.–(BUSINESS WIRE)–Metagenomi, a genetic medicines company with a versatile portfolio of wholly-owned, next-generation gene editing tools, today announced that it has opened a new, in-house Good Manufacturing Practices (GMP) facility, based within its 50,000 square foot campus in Emeryville, California. The agile and modular facility will support the company\u2019s strategy to develop precise gene-editing tools, addressing diseases with high unmet need. This first stage will enable the advancement of Metagenomi\u2019s early clinical proprietary and partnered therapeutic programs.\n<\/p>\n

<\/a><\/p>\n

\n\u201cOur strategic investment in this facility gives us control over the GMP manufacturing of our proprietary nucleases and the industry leading toolbox built on the basis of these nucleases. This facility is designed in a modular way to scale with our increasing number of therapeutic development programs,\u201d said Jian Irish, Ph.D., President and Chief Operating Officer of Metagenomi. \u201cKeeping this facility in-house is important for Metagenomi\u2019s collaborative approach. The proximity to research and development teams that work with best-in-class automation and machine learning systems will ensure seamless development and progression of our large toolbox of innovative gene editing systems.\u201d\n<\/p>\n

\nThe new facility will leverage the scalability of Metagenomi\u2019s diverse gene editing toolbox and create synergy amongst cross-functional teams developing Metagenomi\u2019s proprietary nucleases. Metagenomi\u2019s discovery platform has created the largest library of active nucleases with the ability to edit any codon in the human genome. This library creates the basis for a diverse and proprietary gene editing toolbox that fits a variety of delivery options and is tailored to each therapeutic indication for both in vivo<\/i> and ex vivo<\/i> gene editing approaches. The opening of the new GMP facility will allow for rapid production of Metagenomi\u2019s nucleases to supply both wholly-owned and partnered therapeutic programs.\n<\/p>\n

\n\u201cThe opening of this facility represents a key step in our growth based on our successful funding track record, as we look to further the power of gene editing and bring clinical progress to patients,\u201d said Brian C. Thomas, Ph.D., Founder and CEO of Metagenomi. \u201cOur Emeryville headquarters has enabled us to achieve incredible growth, now with two buildings, and we’re excited to expand our presence in the city, as it emerges as a future hub for biotech companies.\u201d\n<\/p>\n

\nThe new facility is located within Metagenomi\u2019s existing research and development laboratories. The first production in the new facility will take place by the end of 2022.\n<\/p>\n

\nTo learn more about Metagenomi\u2019s pipeline, please visit: https:\/\/metagenomi.co\/pipeline\/<\/a>.\n<\/p>\n

\nAbout Metagenomi<\/b>\n<\/p>\n

\nMetagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines and can be leveraged by partners. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https:\/\/metagenomi.co\/<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMetagenomi<\/b><\/p>\n

Investor:
\n
Simon Harnest
\n
CIO, SVP Strategy
\n
simon@metagenomi.co<\/a>
(917) 403-1051<\/p>\n

Media:
\n
Ashlye Hodge
\n
Sr. Marketing and Communications Specialist
\n
ashlye@metagenomi.co<\/a>
(510) 734-4409\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2022 State-of-the-art GMP facility will support advancement of Metagenomi\u2019s lead pipeline programs and existing partnerships \u2022 New facility at Metagenomi\u2019s Emeryville, CA headquarters delivers on strategic growth plans following successful Series B financing earlier this year EMERYVILLE, Calif.–(BUSINESS WIRE)–Metagenomi, a genetic medicines company with a versatile portfolio of wholly-owned, next-generation gene editing tools, today announced … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49477","6":"format-standard","7":"category-industry"},"yoast_head":"\nMetagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2022 State-of-the-art GMP facility will support advancement of Metagenomi\u2019s lead pipeline programs and existing partnerships \u2022 New facility at Metagenomi\u2019s Emeryville, CA headquarters delivers on strategic growth plans following successful Series B financing earlier this year EMERYVILLE, Calif.–(BUSINESS WIRE)–Metagenomi, a genetic medicines company with a versatile portfolio of wholly-owned, next-generation gene editing tools, today announced ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-11T11:02:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221011005118\/en\/1596090\/21\/Metagenomi-logo_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies\",\"datePublished\":\"2022-10-11T11:02:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\\\/\"},\"wordCount\":601,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005118\\\/en\\\/1596090\\\/21\\\/Metagenomi-logo_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\\\/\",\"name\":\"Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005118\\\/en\\\/1596090\\\/21\\\/Metagenomi-logo_RGB.jpg\",\"datePublished\":\"2022-10-11T11:02:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005118\\\/en\\\/1596090\\\/21\\\/Metagenomi-logo_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005118\\\/en\\\/1596090\\\/21\\\/Metagenomi-logo_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/","og_locale":"en_US","og_type":"article","og_title":"Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies - Pharma Trend","og_description":"\u2022 State-of-the-art GMP facility will support advancement of Metagenomi\u2019s lead pipeline programs and existing partnerships \u2022 New facility at Metagenomi\u2019s Emeryville, CA headquarters delivers on strategic growth plans following successful Series B financing earlier this year EMERYVILLE, Calif.–(BUSINESS WIRE)–Metagenomi, a genetic medicines company with a versatile portfolio of wholly-owned, next-generation gene editing tools, today announced ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-11T11:02:00+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221011005118\/en\/1596090\/21\/Metagenomi-logo_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies","datePublished":"2022-10-11T11:02:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/"},"wordCount":601,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221011005118\/en\/1596090\/21\/Metagenomi-logo_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/","url":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/","name":"Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221011005118\/en\/1596090\/21\/Metagenomi-logo_RGB.jpg","datePublished":"2022-10-11T11:02:00+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221011005118\/en\/1596090\/21\/Metagenomi-logo_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221011005118\/en\/1596090\/21\/Metagenomi-logo_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/metagenomi-announces-opening-of-manufacturing-facility-for-its-next-generation-crispr-gene-editing-systems-and-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49477"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49477\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}